A5035375815- Lipoproteins and Cardiovascular Health
- Pericarditis and Cardiac Tamponade
- Art Education and Development
- Myasthenia Gravis and Thymoma
- Health Systems, Economic Evaluations, Quality of Life
- Ethics in Clinical Research
- Pleural and Pulmonary Diseases
- Pharmaceutical Economics and Policy
- Infective Endocarditis Diagnosis and Management
- Infectious Diseases and Tuberculosis
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Health and Medical Research Impacts
- Biomedical Ethics and Regulation
- Diabetes Treatment and Management
- Creativity in Education and Neuroscience
- Cancer, Lipids, and Metabolism
- Ethics in medical practice
- Pneumocystis jirovecii pneumonia detection and treatment
- Literacy, Media, and Education
- Cultural Industries and Urban Development
- Heart Failure Treatment and Management
- Digital Media and Visual Art
- Metabolism, Diabetes, and Cancer
- Amoebic Infections and Treatments
- Ultrasound in Clinical Applications
Tygerberg Hospital
2011-2024
Stellenbosch University
2009-2023
Regeneron (United States)
2022
University of Liverpool
2019
University of London
2006-2014
The University of Texas Southwestern Medical Center
2014
Université de Montréal
2014
University of Glasgow
2014
SUNY College of Environmental Science and Forestry
2008
State University of New York
2008
Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted 3 trial to evaluate the safety and efficacy of 52 weeks treatment with evolocumab.We stratified patients hyperlipidemia according risk categories outlined by Adult Treatment Panel III National Cholesterol Education Program. On basis this classification, were started on background...
Background— Clinical trials in heart failure have focused on the improvement symptoms or decreases risk of death and other cardiovascular events. Little is known about effect drugs clinical deterioration surviving patients. Methods Results— We compared angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with angiotensin-converting enzyme enalapril (20 8399 patients reduced ejection fraction a double-blind trial. The analyses prespecified measures nonfatal deterioration. In comparison...
Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment lipid-lowering therapies at maximum tolerated doses, an increased risk of atherosclerosis. In such patients, the efficacy and safety subcutaneous intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known.In this double-blind, placebo-controlled, phase 2 trial, we enrolled patients or without heterozygous familial...
Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety efficacy of mipomersen patients with severe was evaluated.Randomized, double-blind, placebo-controlled, multicenter trial. Patients (n = 58) were ≥18 years ≥7.8 mmol/L or ≥5.1 plus CHD disease, on therapy that excluded apheresis. Weekly...
In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in risk for hospitalization or death adults with mild to moderate COVID-19 and factors progression severe disease.
Abstract Background and Aims Lerodalcibep, a novel small recombinant fusion protein of proprotein convertase subtilisin/kexin type 9 gene–binding domain (adnectin) human serum albumin, demonstrated highly effective low-density lipoprotein cholesterol (LDL-C) reduction with monthly 300 mg in 1.2 mL subcutaneous dosing Phase 2. In this global 3 trial, the safety efficacy lerodalcibep were evaluated heterozygous familial hypercholesterolaemia patients requiring additional LDL-C lowering....
Importance Recent changes in national and international lipid guidelines for reducing cardiovascular events recommend additional drugs, greater reductions, lower targets low-density lipoprotein cholesterol (LDL-C) if not attained with statins. The achievement of these proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has yet been evaluated a randomized clinical trial. Objective To evaluate the 52-week safety efficacy lerodalcibep, small anti–PCSK9-binding protein, patients...
In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce risk of primary endpoint through 90 days versus placebo after acute myocardial infarction (MI). Nevertheless, given well-established relationship between higher low-density lipoprotein (LDL-C) and plaque burden, as well greater reductions seen with PCSK9 inhibitors in patients baseline LDL-C ≥100 mg/dL on statin therapy, efficacy...
The aim was to establish the prevalence of large pericardial effusions in Western Cape Province South Africa, and determine incidence various types effusions. A total 233 patients presented with Each patient underwent tests for HIV, sputum smear culture, blood biochemistry serological testing. Tuberculous were diagnosed according pre-determined criteria. Eighty-four (36.1%) found be HIV positive; 81 these (96.4 %) had tuberculous pericarditis. More than 65% study population aged between 15...
BACKGROUND--A statistical audit of adenosine deaminase (ADA) in pleural effusions was undertaken. METHODS--ADA analysis, cytological and microbiological examinations, differential cell counts were performed on 462 fluid samples. RESULTS--ADA activity tuberculous higher than any other diagnostic group. At a level 50 U/l the sensitivity specificity for identification tuberculosis 90% 89%, respectively. CONCLUSIONS--ADA remains useful test evaluation effusions.
Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was enalapril PARADIGM-HF. We made indirect comparisons of effects putative placebos. used treatment-arm Studies Of Left Ventricular Dysfunction (SOLVD-T) as reference trial for comparison an ACE...
To evaluate the efficacy and safety of twice-daily dosing dapagliflozin metformin, exploring feasibility a fixed-dose combination.In this 16-week, phase III, randomized, double-blind placebo-controlled study, adults who were receiving metformin administered twice daily (≥1500 mg/day) had inadequate glycaemic control randomized 1:1:1:1 to receive (2.5 or 5 mg), placebo 10 mg once (which was included as benchmark). The primary endpoint change from baseline glycated haemoglobin (HbA1c) level....
Patients with refractory hypercholesterolemia who do not achieve their guideline-defined low-density lipoprotein cholesterol (LDL-C) thresholds despite treatment maximally tolerated combinations of lipid-lowering therapies (LLTs) have an increased risk atherosclerotic cardiovascular disease (ASCVD).To evaluate longer-term efficacy and safety evinacumab in patients hypercholesterolemia.This randomized clinical trial included a 2-week screening period followed by 16-week double-blind (DBTP)...